Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors

Phase 3

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Haemophilia B With Inhibitors

Interventions: Drug: eptacog alfa (activated)
Drug: vatreptacog alfa (activated)

First Posted Date: 2011-07-12

Last Posted Date: 2017-05-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 72

Registration Number: NCT01392547

Locations: 🇵🇷
Novo Nordisk Clinical Trial Call Center, San Juan, Puerto Rico

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec/liraglutide
Drug: insulin degludec

First Posted Date: 2011-07-12

Last Posted Date: 2019-01-03

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 413

Registration Number: NCT01392573

Locations: 🇨🇭
Novo Nordisk Investigational Site, St. Gallen, Switzerland

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec
Drug: liraglutide
Drug: insulin aspart

First Posted Date: 2011-07-06

Last Posted Date: 2017-03-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 413

Registration Number: NCT01388361

Locations: 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain

Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B

Phase 3

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia B

Interventions: Drug: nonacog beta pegol

First Posted Date: 2011-07-01

Last Posted Date: 2017-08-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 13

Registration Number: NCT01386528

Locations: 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom

Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: insulin degludec/insulin aspart

First Posted Date: 2011-06-03

Last Posted Date: 2017-03-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 276

Registration Number: NCT01365507

Locations: 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey

A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa

First Posted Date: 2011-06-03

Last Posted Date: 2017-02-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 4

Registration Number: NCT01365520

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec

First Posted Date: 2011-06-02

Last Posted Date: 2017-03-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 373

Registration Number: NCT01364428

Locations: 🇺🇸
Novo Nordisk Investigational Site, Renton, Washington, United States

Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: repaglinide

First Posted Date: 2011-05-18

Last Posted Date: 2014-08-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 120

Registration Number: NCT01355718

A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in India

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Diabetes

Interventions: Other: No treatment given

First Posted Date: 2011-05-11

Last Posted Date: 2017-01-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 12000

Registration Number: NCT01351922

Locations: 🇮🇳
Novo Nordisk Investigational Site, Bangalore, India

Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide

First Posted Date: 2011-05-02

Last Posted Date: 2018-12-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1056

Registration Number: NCT01345734

Locations: 🇵🇭
Novo Nordisk Investigational Site, Manilla, Philippines

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy